The Court of Appeals for the Federal Circuit in Washington found Boston Scientific Corporation's Ding patent invalid, and reversed a 2005 jury finding that Cordis Corporation's Cypher Sirolimus-eluting Coronary Stent infringed that patent.

The original jury verdict was rendered in July 2005 in Wilmington, Delaware. The Ding patent had claimed a two-layer drug coating for a drug-eluting stent, which the Appeals Court found to be obvious in light of earlier issued patents.

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology.